Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-055689
Filing Date
2026-05-05
Accepted
2026-05-05 16:41:24
Documents
77
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20260331x10q.htm   iXBRL 10-Q 1347161
2 EX-31.1 tmb-20260331xex31d1.htm EX-31.1 13971
3 EX-32.1 tmb-20260331xex32d1.htm EX-32.1 5936
4 GRAPHIC tmb-20260331x10q001.jpg GRAPHIC 40637
  Complete submission text file 0001104659-26-055689.txt   7005260

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20260331.xsd EX-101.SCH 61734
6 EX-101.CAL tmb-20260331_cal.xml EX-101.CAL 56119
7 EX-101.DEF tmb-20260331_def.xml EX-101.DEF 191261
8 EX-101.LAB tmb-20260331_lab.xml EX-101.LAB 487487
9 EX-101.PRE tmb-20260331_pre.xml EX-101.PRE 347500
81 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20260331x10q_htm.xml XML 1166487
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 26944034
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)